Research Paper Volume 13, Issue 7 pp 10450—10467

RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma

Oncogenic role of RIPK2 in human kidney cancer. (A) Change of RIPK2 mRNA expression between tumor samples and normal samples from TCGA KIRC studies. (B) Dot plot showing the positive correlation between RIPK2 copy number values defined by GISTIC2 approach and mRNA expression values quantified by FPKM. (C) Dot plot showing the correlation between RIPK2 methylation values defined by HM450 approach and mRNA expression values quantified by FPKM. (D) Kaplan–Meier survival curve comparing the high and low expression value of RIPK2 (determined by the mean or quantile value) for the TCGA KIRC patient cohort. Statistical significance was determined by one-way ANOVA and the log-rank test.

Figure 1. Oncogenic role of RIPK2 in human kidney cancer. (A) Change of RIPK2 mRNA expression between tumor samples and normal samples from TCGA KIRC studies. (B) Dot plot showing the positive correlation between RIPK2 copy number values defined by GISTIC2 approach and mRNA expression values quantified by FPKM. (C) Dot plot showing the correlation between RIPK2 methylation values defined by HM450 approach and mRNA expression values quantified by FPKM. (D) Kaplan–Meier survival curve comparing the high and low expression value of RIPK2 (determined by the mean or quantile value) for the TCGA KIRC patient cohort. Statistical significance was determined by one-way ANOVA and the log-rank test.